Progressive Retinal Dystrophy Due To Retinol Transport Defect — Comprehensive Disease Report

Summary

Progressive retinal dystrophy due to a retinol transport defect is a rare inherited retinal degeneration caused primarily by biallelic (autosomal recessive) loss-of-function variants in RBP4, the gene encoding serum retinol-binding protein 4 (chromosome 10q23.33). RBP4 is the sole specific plasma carrier that mobilizes vitamin A (all-trans retinol) from hepatic stores and delivers it to peripheral tissues, most critically the eye. When circulating RBP4 is absent or non-functional, the retina is starved of the retinoid chromophore required to regenerate visual pigment, even though liver vitamin A stores remain intact. The result is a systemic ("inherited") vitamin A deficiency with a retina-dominant phenotype: childhood-onset night blindness (nyctalopia), reduced visual acuity, and progressive rod–cone/retinal pigment epithelium (RPE) degeneration, frequently accompanied by iris and chorioretinal colobomata, severe comedogenic acne, and, in some pedigrees, developmental anomalies such as patent ductus arteriosus.

The distinctive diagnostic biochemical signature separates this disorder from ordinary dietary vitamin A deficiency: serum RBP4 is undetectable, serum retinol is very low (~1/6 of normal), retinyl esters are normal, transthyretin is normal, and serum retinol fails to rise with oral vitamin A dosing because there is no carrier to mobilize the vitamin from the liver. Electrophysiology shows reduced scotopic ERG responses and elevated dark-adaptation thresholds. Mechanistically related disease arises from defects in the retinol uptake receptors STRA6 and RBPR2, which extract retinol from RBP4 at blood–tissue barriers (RPE, choroid plexus). These genes define a broader "liver–eye vitamin A axis."

A key refinement discovered across the investigation is a genotype–inheritance–phenotype dichotomy: recessive, mainly truncating RBP4 alleles produce retinal degeneration, whereas dominant, almost exclusively missense alleles produce ocular malformations (microphthalmia–anophthalmia–coloboma, MAC), with a maternal-effect component—consistent with the dual role of the retinoic-acid/vitamin-A pathway in both eye morphogenesis and the visual cycle. Management is empirical high-dose vitamin A supplementation (rescue demonstrated in Stra6-knockout mice), with AAV gene therapy proposed given the small size of RBP4.

Key Findings

Finding 1 — RBP4 is the causal gene; biallelic loss-of-function drives disease via vitamin A transport failure

Multiple independent consanguineous pedigrees establish recessive RBP4 variants as the cause of progressive retinal dystrophy. Reported pathogenic alleles include a homozygous splice-site variant c.111+1G>A (PMID: 23189188), a homozygous variant c.67C>T (PMID: 32323592), and biallelic c.248+1G>A (PMID: 27892788). Across these families, affected patients had undetectable serum RBP4, severe vitamin A deficiency, and low serum retinol, with normal transthyretin—collectively establishing a null / loss-of-function mechanism rather than a transport-complex assembly defect.

"Exome sequencing identified a novel homozygous splice site variant (c.111+1G>A) in the gene encoding retinol binding protein 4 (RBP4)." — PMID: 23189188

"Both patients had undetectable levels of RBP4 in the serum suggesting that this mutation led to either mRNA or protein instability resulting in a null phenotype." — PMID: 23189188

"Bi-allelic mutations in RBP4 were identified (c.248+1G>A), consistent with a diagnosis of inherited vitamin A deficiency." — PMID: 27892788

Ontology anchors: Gene HGNC:9922 (RBP4); OMIM gene 180250. GO biological process: retinol transport (GO:0034633), retinoid metabolic process (GO:0001523).

Finding 2 — Characteristic multisystem phenotype

The clinical picture spans the eye and beyond. Ocular features include night blindness and low vision from early childhood with fundus findings typical of recessive retinitis pigmentosa (PMID: 32323592), and retinal dystrophy combined with iris/chorioretinal colobomata (PMID: 27892788, PMID: 23189188). Extraocular features include severe childhood-onset acne vulgaris that segregates with the RBP4 genotype (PMID: 32323592, PMID: 23189188) and developmental abnormalities such as patent ductus arteriosus (PMID: 23189188).

"presented with low vision and night blindness from early childhood" — PMID: 32323592

"confirming that mutations in RBP4 segregated with the acne vulgaris phenotype in this family" — PMID: 32323592

"one patient exhibited developmental abnormalities including patent ductus arteriosus and chorioretinal and iris colobomas" — PMID: 23189188

Suggested HPO terms: Nyctalopia/night blindness (HP:0000662); Retinal dystrophy (HP:0000556); Rod-cone dystrophy (HP:0000510); Reduced visual acuity (HP:0007663); Iris coloboma (HP:0000612); Chorioretinal coloboma (HP:0000567); Acne (HP:0031287); Patent ductus arteriosus (HP:0001643).

Finding 3 — Mouse models recapitulate the dystrophy and demonstrate rescue by pharmacological vitamin A

Rbp4-deficient mice on a C57BL/6 background show reduced ERG a- and b-wave amplitudes, loss of peripheral choroid and photoreceptor layer, fewer ganglion cells and synapses, and developmental defects (retinal depigmentation, optic disc abnormality, persistent hyaloid artery). Their biochemistry mirrors humans: serum retinol was undetectable while liver retinol accumulated (PMID: 26974396). Stra6-knockout mice show markedly reduced ocular retinoids, choroid/RPE malformations, early cone death, and short rod outer segments—and, crucially, high-dose vitamin A rescues vision (PMID: 24852372).

"loss of the peripheral choroid and photoreceptor layer in the peripheral retinas" — PMID: 26974396

"accumulated retinol in the liver but it was undetectable in the serum" — PMID: 26974396

"treatment with pharmacological doses of vitamin A restored vitamin A transport across these barriers and rescued the vision of Stra6(-/-) mice" — PMID: 24852372

This is the single strongest piece of translational evidence supporting empirical vitamin A supplementation as therapy.

Finding 4 — Genetic heterogeneity of the retinol-transport axis (RBP4 → STRA6 / RBPR2)

The disorder is one node in a multigene "liver–eye vitamin A axis." RBP4 is the blood carrier; cellular uptake of retinol is receptor-mediated. STRA6 is highly expressed in epithelia forming blood–tissue barriers (RPE, choroid plexus), and its loss causes reduced ocular retinoids, RPE malformation, and cone death (PMID: 24852372). A second systemic receptor, RBPR2, when knocked out in mice, shows decreased ocular retinoids and loss of visual function (PMID: 35745101). The axis is integrated in a recent review (PMID: 41829974).

"This receptor, identified as the Stimulated by retinoic acid gene 6 (Stra6) gene product, is highly expressed in epithelia that constitute blood-tissue barriers." — PMID: 24852372

"Blood transport of the lipophilic vitamin is mediated by the retinol-binding protein, RBP4." — PMID: 24852372

Related genes/ontology: STRA6 (HGNC:30650), RBPR2 (HGNC:34333), TTR (transthyretin, RBP4's stabilizing partner). GO cellular component: extracellular space (GO:0005615); apical plasma membrane (GO:0016324) for STRA6 at the RPE.

Finding 5 — The founding human family defines the diagnostic signature

Seeliger et al. 1999 (PMID: 9888420) described the first human RBP4 patients: two affected sisters with compound heterozygous missense mutations Ile41Asn (I41N) and Gly75Asp (G75D). Their labs defined the phenotype: all-trans retinol 0.18–0.19 µM (normal 0.7–1.5 µM) that did not increase in a dose-response test, RBP below detection threshold, and normal retinyl esters. Clinically: night vision problems, reduced acuity (20/25–20/40), discrete iris coloboma, "fundus xerophthalmicus" with RPE atrophy, elevated dark-adaptation thresholds, reduced scotopic ERG, abnormal EOG light rise, and acne.

"RBP was below detection threshold, and retinyl esters were normal." — PMID: 9888420

"did not increase in a dose-response test" — PMID: 9888420

"compound heterozygous missense mutations (Ile41Asn and Gly75Asp) in the gene for serum retinol binding protein (RBP)" — PMID: 9888420

The failure of serum retinol to rise with oral vitamin A is a pivotal treatment caveat: because RBP4 is required to mobilize hepatic retinol, systemic delivery may be limited, and the therapeutic effect (as in Stra6 mice) likely depends on mass-action/pharmacological dosing rather than restoring the physiological carrier.

Finding 6 — Genotype–inheritance dichotomy with a maternal-effect component

Plaisancié et al. 2023 (PMID: 37586836), studying 7 new families / 13 patients, resolved the phenotypic spectrum into two modes:

"dominantly inherited, almost exclusively missense, associated with ocular malformations, in contrast to recessive, mainly truncating, associated with retinal degeneration" — PMID: 37586836

"The retinoic acid (RA) pathway plays a crucial role in both eye morphogenesis and the visual cycle." — PMID: 37586836

The dominant, malformation-causing alleles show skewed (maternal) inheritance—consistent with a maternal-effect mechanism whereby maternal RBP4 status influences retinoic-acid signaling during fetal eye morphogenesis.

Mechanistic Model / Interpretation

Causal chain (initiating lesion → clinical manifestation)

1. Biallelic loss-of-function variant in RBP4 (splice-site, nonsense, or destabilizing missense) → leads to absent or non-functional serum retinol-binding protein 4 (undetectable serum RBP4).
2. Absent RBP4 → results in failure to mobilize all-trans retinol from hepatic stores into the bloodstream; liver retinol is retained/accumulates while serum retinol falls to ~1/6 normal (demonstrated in humans and Rbp4-KO mice).
3. Low circulating retinol → deprives the retinal pigment epithelium of substrate for the visual (retinoid) cycle; STRA6/RBPR2-mediated uptake at the RPE has no ligand to extract.
4. Chromophore deprivation → impairs regeneration of 11-cis-retinal / rhodopsin in rod (then cone) photoreceptors → manifests first as night blindness (rods most retinoid-dependent).
5. Chronic chromophore starvation → causes progressive photoreceptor and RPE degeneration and peripheral choroid loss → progressive retinal dystrophy / RP-like phenotype with reduced ERG and elevated dark-adaptation thresholds.
6. Branch (developmental / dominant-missense arm): deficient retinoic-acid signaling during embryonic eye morphogenesis → results in ocular malformations (iris/chorioretinal coloboma; microphthalmia–anophthalmia–coloboma spectrum), influenced by maternal RBP4 status (maternal effect). (Inferred from the RA-pathway role in morphogenesis rather than directly demonstrated in these pedigrees.)
7. Branch (systemic retinoid signaling): low tissue retinoid tone in skin → contributes to dysregulated follicular keratinization and severe acne vulgaris; other developmental effects (e.g., patent ductus arteriosus) reflect retinoid-dependent organogenesis. (Skin/PDA links are phenotypically associated and mechanistically inferred.)

The liver–eye vitamin A axis (schematic)

   LIVER (retinyl ester stores)
        |  hydrolysis -> retinol
        v
   [ RBP4 ] <-- stabilized by TTR -->  BLOODSTREAM (retinol.RBP4.TTR)
        |                                   X  <-- LESION: no RBP4 -> no carrier
        v
   BLOOD-TISSUE BARRIER (RPE, choroid plexus)
        |  STRA6 / RBPR2 receptor uptake
        v
   RPE  -> visual (retinoid) cycle -> 11-cis-retinal
        |
        v
   PHOTORECEPTORS (rods > cones): rhodopsin regeneration
        |  chromophore starvation
        v
   Night blindness -> progressive rod-cone/RPE degeneration

Upstream vs downstream

Cell types and processes

• Cell Ontology (CL): retinal rod cell (CL:0000604); retinal cone cell (CL:0000573); retinal pigment epithelial cell (CL:0002586); retinal ganglion cell (CL:0000740); hepatic stellate cell (CL:0000632, retinoid storage).
• UBERON anatomy: retina (UBERON:0000966); retinal pigment epithelium (UBERON:0001782); choroid (UBERON:0002348); iris (UBERON:0001769); liver (UBERON:0002107).
• GO biological processes: visual perception (GO:0007601); retinoid metabolic process (GO:0001523); retinol transport (GO:0034633); retina development in camera-type eye (GO:0060041); photoreceptor cell maintenance (GO:0045494).
• CHEBI chemical entities: retinol / vitamin A (CHEBI:17336); all-trans-retinol (CHEBI:50211); 11-cis-retinal (CHEBI:16066); retinyl ester (CHEBI:63410); retinoic acid (CHEBI:26536).

Evidence Base

Note on the anorexia case (PMID: 17646742): dietary hypovitaminosis A produces overlapping retinal dysfunction (impaired scotopic ERG, RP-like field constriction) but is corrected by supplementation and features prominent xerophthalmia—underscoring that the inherited transport defect is distinguished by undetectable RBP4, normal retinyl esters, and poor response to oral vitamin A.

Section-by-Section Knowledge Base Content

1. Disease Information

Inherited retinal degeneration from failed plasma vitamin A transport. Synonyms: RBP4-related retinal dystrophy; inherited/systemic vitamin A deficiency; retinol-binding protein deficiency; "fundus xerophthalmicus" (historical). Identifiers: Gene RBP4 OMIM 180250; disease phenotype OMIM #615147 (RBP4-related retinal dystrophy / "Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, RDCCAS"). Suggested MONDO: map to the RBP4-related inherited vitamin A deficiency / retinal-dystrophy branch. ICD-10 H35.5 (hereditary retinal dystrophy). Information is derived from aggregated disease-level resources and small pedigree case series, not large EHR cohorts.

2. Etiology

Primary cause: genetic—biallelic (recessive) LoF RBP4 variants (retinal degeneration) or monoallelic dominant missense (ocular malformation). Genetic risk factors: consanguinity (most recessive families are consanguineous). Modifier/environmental: dietary vitamin A status may modulate severity; there are no established protective alleles. Gene–environment interaction: because the block is at transport, dietary vitamin A alone does not normalize serum retinol, but pharmacological loading may partially bypass the deficit (mass-action delivery).

3. Phenotypes

Night blindness (HP:0000662, early childhood, progressive, high frequency); retinal dystrophy/rod–cone dystrophy (HP:0000556/HP:0000510, progressive); reduced visual acuity (HP:0007663); iris coloboma (HP:0000612) and chorioretinal coloboma (HP:0000567, subset); acne (HP:0031287, severe, childhood-onset, variable); patent ductus arteriosus (HP:0001643, rare). QoL impact is dominated by progressive low vision and nyctalopia affecting mobility and independence.

4. Genetic/Molecular Information

Causal gene: RBP4 (HGNC:9922; 10q23.33; OMIM 180250). Variant classes: splice-site (c.111+1G>A; c.248+1G>A), c.67C>T, and missense (I41N/G75D; dominant missense in MAC). Classification: pathogenic/likely pathogenic per ACMG for the recessive truncating alleles. Functional consequence: loss of function / null (undetectable serum RBP4) for recessive disease; the dominant missense alleles are proposed to act via altered retinoid signaling. Modifier genes: STRA6, RBPR2, TTR within the same axis. Epigenetic and chromosomal abnormalities: none established.

5. Environmental Information

Dietary vitamin A intake is the principal modifiable variable but cannot correct the transport block at physiological doses. No infectious agents. Acquired (dietary/malabsorptive) vitamin A deficiency is an important phenocopy for differential diagnosis.

6. Mechanism / Pathophysiology

See "Mechanistic Model" above for the full ordered causal chain, pathway map, and ontology anchors.

7. Anatomical Structures Affected

Primary organ: eye—retina (UBERON:0000966), RPE (UBERON:0001782), choroid (UBERON:0002348), iris (UBERON:0001769). Secondary: liver (retinoid storage; UBERON:0002107), skin (acne), cardiovascular (PDA). Cells: rods (CL:0000604), cones (CL:0000573), RPE (CL:0002586). Subcellular: RPE endosomal/visual-cycle machinery; photoreceptor outer segments. Lateralization: bilateral, generally symmetric.

8. Temporal Development

Onset: childhood (night blindness/low vision from early childhood). Course: chronic, slowly progressive rod–cone/RPE degeneration; developmental/malformation features are congenital. Critical period: embryonic eye morphogenesis (for coloboma/MAC via retinoic-acid signaling) and early postnatal photoreceptor maintenance.

9. Inheritance and Population

Inheritance: autosomal recessive (retinal degeneration; often consanguineous) vs autosomal dominant missense (ocular malformation, with maternal-effect skewing). Prevalence: ultra-rare; only a handful of families reported worldwide—no reliable population estimate. Penetrance/expressivity: variable expressivity across ocular and extraocular features. Founder effects not established; consanguinity is a strong contributor for recessive cases.

10. Diagnostics

Biochemistry (key): undetectable serum RBP4, very low serum retinol, normal retinyl esters, normal transthyretin; serum retinol does not rise with oral vitamin A. Electrophysiology: reduced scotopic ERG, elevated dark-adaptation thresholds, abnormal EOG light rise. Imaging/fundus: RP-like RPE atrophy, peripheral pigmentary change, coloboma. Genetics: WES/WGS or inherited-retinal-dystrophy gene panels including RBP4 (and STRA6, RBPR2); single-gene confirmation of biallelic RBP4 variants. Differential: dietary/malabsorptive vitamin A deficiency (normalizes with supplementation; RBP4 present), other recessive RP, Leber congenital amaurosis (visual-cycle genes; PMID: 34440435).

11. Outcome/Prognosis

Vision is progressively impaired; night blindness and low vision are the dominant disabilities. Not typically life-limiting (extraocular features—PDA—are exceptions). No large survival data; prognosis is driven by degree of retinal degeneration at diagnosis and potential responsiveness to vitamin A loading.

12. Treatment

Mainstay: empirical high-dose (pharmacological) vitamin A supplementation (NCIT: Vitamin A / Retinol Therapy). Rationale is strong preclinically—vitamin A rescued vision in Stra6-KO mice (PMID: 24852372)—but the human treatment caveat is that serum retinol may not normalize because RBP4 is absent (PMID: 9888420); benefit likely depends on mass-action delivery to the eye. Supportive: low-vision rehabilitation; dermatologic management of acne. Investigational: AAV-mediated RBP4 gene replacement is a rational strategy given the small gene and the null mechanism (no approved therapy yet; no NCT identified in this investigation).

13. Prevention

Genetic counseling for consanguineous/at-risk families; carrier and cascade testing; prenatal/preimplantation options for known family variants. Ensuring adequate maternal vitamin A status is prudent given the retinoic-acid morphogenesis link, though it does not overcome the transport block.

14. Other Species / Natural Disease

Disease modeled and mechanistically dissected in mouse (Mus musculus, NCBI:txid10090): Rbp4⁻/⁻ (PMID: 26974396), Stra6⁻/⁻ (PMID: 24852372), Rbpr2⁻/⁻ (PMID: 35745101). Orthologs: mouse Rbp4 (NCBI Gene 19662). No specific companion-animal natural disease was identified in this investigation.

15. Model Organisms

Mammalian genetic knockouts are the principal models. Rbp4⁻/⁻ mice recapitulate the human biochemical signature (serum retinol undetectable, liver retinol retained) and structural degeneration (photoreceptor/choroid loss, reduced ERG). Stra6⁻/⁻ mice add the therapeutic proof-of-concept (vitamin A rescue). Limitations: background-dependent severity (C57BL/6 shows severe ocular phenotypes); mouse retinoid handling and rod-dominance differ from human macula, so cone/macular outcomes may be imperfectly modeled.

Limitations and Knowledge Gaps

• Ultra-rare disease, tiny N. Conclusions rest on a small number of consanguineous pedigrees and case series; there are no cohort-level prevalence, penetrance, or natural-history data.
• Treatment evidence is largely preclinical. Vitamin A rescue is proven in Stra6-KO mice, but human treatment response—especially whether high-dose vitamin A halts or reverses retinal degeneration—is not established in controlled studies, and serum retinol may not normalize.
• Extraocular mechanism inferred. The links from RBP4 loss to acne and to PDA are phenotypic associations with mechanistic inference (retinoid signaling) rather than direct experimental proof in these families.
• Dominant-missense/MAC arm is newer and less mechanistically resolved; the maternal-effect basis needs functional confirmation.
• No approved gene therapy or registered clinical trial was identified; AAV replacement remains conceptual.
• Some cited resources (PMID: 41829974) lacked accessible abstracts, limiting verbatim support.

Proposed Follow-up Experiments / Actions

1. Prospective vitamin A dosing trial in genetically confirmed RBP4-null patients with serial ERG, dark-adaptation, OCT, and serum retinol/RBP4 to quantify whether pharmacological loading slows degeneration and to define the effective dose.
2. AAV-RBP4 gene-replacement proof-of-concept in Rbp4⁻/⁻ mice (liver-directed vs intravitreal/RPE-directed) measuring serum retinol restoration and ERG rescue; compare with vitamin A loading.
3. Genotype–phenotype meta-analysis aggregating all reported RBP4 families to formalize the recessive-truncating (degeneration) vs dominant-missense (malformation) dichotomy and estimate expressivity/penetrance.
4. Mechanistic dissection of extraocular features—retinoid profiling of skin and assessment of developmental cardiovascular phenotypes in Rbp4-KO models—to test the retinoid-signaling basis of acne and PDA.
5. Diagnostic algorithm validation: prospectively confirm that the triad "undetectable RBP4 + low retinol + normal retinyl esters + non-response to oral vitamin A" reliably distinguishes inherited transport defect from acquired/dietary deficiency.
6. Registry/consortium for RBP4, STRA6, and RBPR2 patients to enable natural-history and future interventional studies.

Evidence source legend: Human clinical/genetic — PMIDs 9888420, 23189188, 27892788, 32323592, 37586836. Model organism — PMIDs 26974396, 24852372, 35745101. Review/context — PMIDs 41829974, 34440435, 17646742.